The global therapeutic medicinal cannabis company is currently undertaking human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA as well a pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.
Shares in Zelira Therapeutics (ASX:ZLD) closed flat at $0.07 yesterday.